UNSPSC 51162016: Calcium iodide/isoproterenol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162016 Calcium iodide/isoproterenol is a Commodity code, but recent state and local procurement activity under this code does not align with the nominal pharmaceutical substance. The four opportunities posted between January and July 2026 solicit naloxone and drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are calcium iodide or isoproterenol formulations. The code appears to be a categorization mismatch in state and local procurement systems, suggesting that vendors pursuing opportunities actually tagged under 51162016 will encounter scope misalignment between the code's name and the work being bought.

Activity spans Florida, Georgia, Minnesota, Texas, and Oregon through Seminole County (IFB for naloxone and drug deactivation systems, due July 26, 2023), Hall County, Georgia (RFQ/P for on-site pharmacy services, due June 4, 2026), the Texas Health and Human Services Commission (RFI for direct-to-manufacturer prescription programs, April 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (RFP for generic pharmaceuticals and OTC products via authorized wholesalers, due March 26, 2026). The scope divergence between the code's nominal definition and actual procurement activity indicates that this code does not reliably predict state and local buying patterns in pharmaceutical supply or pharmacy services. Vendors should verify code alignment in specific RFPs and RFQs rather than relying on the 51162016 classification to identify relevant opportunities.